CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
Congratulations to these trial teams and their member centres for their efforts and dedication to the success of CCTG clinical trials, these recipients were announced at the 2021 CCTG Annual Spring Meeting of Participants last week.
Congratulations to the 2021 Winners Dr. Michael Ong and Dr. Albiruni Abdul Razak announced at the CCTG Spring Meeting last week. The Elizabeth Eisenhauer Young Investigator Award is presented to any MD, fellow, or PhD, within 7 years of certification / first faculty appointment, or current fellow who has either spent time at CCTG Central Office, worked on projects with the Investigational New Drug (IND) Program or who has contributed significantly to the conduct of an IND trial at a participating centre.
Reporting to the Manager, Office of Compliance and Oversight (OCO), the Audit and Monitoring Group (AMG) Team Leader will lead one of the two teams in AMG, namely the Canadian On-Site Monitoring Team OR the Residual and International Monitoring Teams. The AMG Team Leader will ensure AMG standard operating procedures are followed to ensure compliance with applicable guidelines, regulations and standards.
The #CCTG2021 Virtual Spring Meeting is less than a month away!
The first round of invitations has been sent so check your inbox for your invitation email. If you cannot find your e-invitation in your inbox, please check your trash or spam folders. If you need to have your e-invitation re-sent please e-mail us at meeting.spring@ctg.queensu.ca.
Dr. Elizabeth Eisenhauer, former CCTG IND Program Director and CCTG Interim Group Director, has been presented with the 2021 Canada Gairdner Wightman Award, for her dedication to transforming the fields of cancer clinical trials and cancer drug delivery.
Evaluate the ability to predict survival benefit from adjuvant chemotherapy in early stage non-small cell lung cancer (NSCLC), and
